Personal view article on 'Redefining plasma cell leukemia,' co-authored by IMF Chairperson of the Board Dr. S. Vincent Rajkumar and IMF Scientific Advisory Board Member Dr. Shaji Kumar, was recently published in The Lancet Haematology.

Published in The Lancet Haematology and co-authored by International Myeloma Foundation (IMF) Chairperson of the Board Dr. S. Vincent Rajkumar and IMF Scientific Advisory Board Member Dr. Shaji Kumar, this personal view article "calls for plasma cell leukemia to be considered as high-risk myeloma and not as a unique disease," states Dr. Rajkumar on X/Twitter.

According to Dr. Rajkumar, "with the revision of IMS/IMWG high-risk myeloma definition to make it stricter, and relaxation of diagnostic criteria for plasma cell leukemia to 5% PCs, the two groups have come closer in outcomes. They share a need for new ways overcome risk and improve prognosis with unified clinical trials. We also need to eliminate confusion for patients."

"In our view, Plasma Cell Leukemia is a form of high-risk myeloma. The term captures risk the same way del17 or EMD captures risk," he further added.

The study may be viewed or downloaded for a limited time here.